5 Stocks Insiders Are Snapping Up: Seattle Genetics and More
at The Street - Wed Dec 24, 7:22AM CST
Insiders usually buy their own shares because they think the stock is a bargain and has tremendous upside.
GLP: 34.90 (-0.19), SGEN: 31.10 (-0.14), HDS: 29.72 (+0.01), SJW: 32.40 (+0.28), PAH: 23.00 (+0.01)
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger?
Cheryl Swanson - at Seeking Alpha - Tue Dec 23, 10:21AM CST
SGEN: 31.10 (-0.14), AGIO: 109.67 (+2.45), CELG: 109.60 (+3.48)
Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research, Sunesis Pharma, Array BioPharma, and Seattle Genetics
PR Newswire - Mon Dec 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Arrowhead Research Corporation (NASDAQ: ARWR), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Array BioPharma Inc. (NASDAQ: ARRY), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 19, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,804.80, up 0.15% and the NASDAQ Composite closed at 4,765.38, up 0.36%. The S&P 500 finished the session 0.46% higher at 2,070.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 816.95, up 0.41%, with the index advancing 9.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SGEN: 31.10 (-0.14), ARWR: 6.35 (+0.07), ACHN: 13.06 (+1.22), SNSS: 2.48 (-0.03), ARRY: 4.64 (+0.07)
Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 10:20AM CST
Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
CYTK: 5.87 (+0.35), BIIB: 340.89 (+5.13), SGEN: 31.10 (-0.14), AMGN: 160.67 (+3.15)
Zacks' Bull Of The Day: Seattle Genetics
Zacks Investment Research - Seeking Alpha - Fri Dec 19, 8:14AM CST
Seattle Genetics (NASDAQ: SGEN ) is a $4 billion biotechnology company focused on developing and commercializing innovative antibody-based therapies for the treatment of cancer. They are the industry leaders in antibody-drug conjugates (ADCs), a...
SGEN: 31.10 (-0.14)
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Fri Dec 19, 12:00AM CST
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
PCYC: 121.84 (+1.15), SGEN: 31.10 (-0.14), INCY: 71.57 (+1.99), MRK: 57.46 (+0.25), AGIO: 109.67 (+2.45), BMY: 59.15 (-0.01)
Seattle Genetics: Good Tech, But On The Wrong Path
Owen Zeng - at Seeking Alpha - Thu Dec 18, 5:42PM CST
SGEN: 31.10 (-0.14)
Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia
Business Wire - Thu Dec 18, 8:00AM CST
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen. SGN-CD33A is a novel antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity. SGN-CD33A is also under evaluation in an ongoing phase 1 dose escalation trial as a single-agent or in combination with hypomethylating agents for the treatment of patients who have relapsed AML or have declined intensive frontline therapy.
SGEN: 31.10 (-0.14)
InsiderInsights.com Daily Round Up 12/17/14: HTZ, NAV, ENH, AIRT
InsiderInsights - at Seeking Alpha - Thu Dec 18, 3:35AM CST
CNXR: 8.90 (+0.15), HTZ: 24.38 (-0.09), ZSPH: 43.93 (+1.77), ISIG: 3.78 (+0.02), WMS: 23.00 (+0.28), AIRT: 24.17 (+0.03), MAR: 78.35 (-0.19), RL: 184.35 (+0.70), ADBE: 74.74 (+0.36), CI: 104.23 (-0.08), AMH: 17.34 (-0.07), WIW: 11.28 (+0.03), NOW: 69.69 (+0.12), SGEN: 31.10 (-0.14), BEAV: 58.63 (-0.02), NAV: 33.81 (-0.11), AGIO: 109.67 (+2.45), AI: 27.70 (-0.12), ENH: 59.60 (-0.55)
InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST
TRVN: 5.38 (-0.37), HSGX: 10.51 (-0.46), VR: 41.51 (+0.19), LBTYK: 49.10 (+0.05), ATLS: 30.37 (-0.07), UHS: 111.87 (+0.99), CLH: 49.40 (-0.60), WMS: 23.00 (+0.28), ALEX: 40.09 (+0.38), CDW: 35.75 (+0.14), BABY: 36.45 (+1.14), PRSS: 2.42 (-0.01), SGEN: 31.10 (-0.14), CO: 4.40 (+0.05), HBI: 110.93 (-0.07), TWI: 10.92 (-0.20), HSIC: 137.87 (+0.15), PSEC: 8.59 (-0.02), XLRN: 38.80 (+0.80)
Seattle Genetics Is Offering Growth, For A Price
Cory Renauer - at Seeking Alpha - Wed Dec 10, 12:06PM CST
SGEN: 31.10 (-0.14)
Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting
Business Wire - Mon Dec 08, 6:30PM CST
--Phase 1b Combination Trial Planned to Evaluate SGN-CD33A with Standard of Care in Frontline and Consolidation Settings for Acute Myeloid Leukemia
SGEN: 31.10 (-0.14)
Seattle Genetics Presents ADCETRIS(R) (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting
Business Wire - Mon Dec 08, 6:30PM CST
---Phase 2 Randomized Trial Planned for Relapsed/Refractory CD30-Positive DLBCL-
SGEN: 31.10 (-0.14)
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 4:10PM CST
Bristol-Myers Squibb Company (BMY) announced encouraging data from the ongoing phase Ib CheckMate - 039 study on Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), SGEN: 31.10 (-0.14), BMY: 59.15 (-0.01)
Seattle Genetics-Takeda's Adcetris Shows Long-Term Effect - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:20PM CST
Seattle Genetics, Inc. (SGEN) and Takeda announced four-year overall survival data from a pivotal phase II study on Adcetris for systemic anaplastic large cell lymphoma.
BIIB: 340.89 (+5.13), SGEN: 31.10 (-0.14), AMGN: 160.67 (+3.15)
Merck's New Oncology Product Positive in Early Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:10PM CST
Merck (MRK) announced encouraging early results from the ongoing phase Ib study on Keytruda.
AGN: 210.12 (+0.95), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST
SGEN: 31.10 (-0.14), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07)
Seattle Genetics Highlights Multiple ADCETRIS(R) (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting
Business Wire - Mon Dec 08, 9:00AM CST
---ADCETRIS in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma as Second-line Therapy Shows Objective Response Rate of 96 Percent and Complete Remission Rate of 83 Percent-
SGEN: 31.10 (-0.14)
The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 88.76 (+3.23), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), SNSS: 2.48 (-0.03), AGIO: 109.67 (+2.45), BMY: 59.15 (-0.01), XLRN: 38.80 (+0.80), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48)